Federal Initiative Expands Medicaid Access to High-Cost Sickle Cell Gene Therapies Across 33 States
The participating states represent approximately 84% of Medicaid beneficiaries with sickle cell disease
Advertisement
Advertisement
Advertisement

Urban Health Weekly